Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and… bypharmanewsdailyJuly 15, 2020